poisar

Stocks · News reference

This Capricor Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Avi Kapoor

Wall Street analysts revised their ratings for top stocks. Visit benzinga.com/analyst-stock-ratings for all changes, including upgrades and downgrades.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

CAPRCSQRDLRLUNRNERVNYAXUAA
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Kahn Swick & Foti, Llc

    Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

    Kahn Swick & Foti, LLC announces a class action securities lawsuit against Capricor Therapeutics for failing to disclose material information regarding changes to its statistical analysis plan for its lead drug candidate Deramiocel. The FDA found the company made undisclosed modifications to the analysis plan just before data unblinding, which the agency deemed post-hoc and exploratory. Following FDA briefing documents on July 27, 2026, Capricor's stock plummeted 64% to $7.00 per share. Investors who purchased shares between December 17, 2025 and July 26, 2026 can apply to join the lawsuit by September 28, 2026.

    CAPR
  2. Kirby Mcinerney Llp

    Kirby McInerney LLP Alerts Investors Who Acquired Bloom Energy Corporation BE Securities Between February 27, 2025 and July 8, 2026 of Pending Lawsuit

    Law firm Kirby McInerney LLP announced pending securities class action lawsuits against Bloom Energy Corporation for allegedly making false statements about its reliance on Chinese scandium supplies. A short-seller report on July 8, 2026 revealed that Bloom Energy sourced scandium from China through intermediaries despite claiming minimal China supply chain dependence, causing the stock to fall 5.7%. The firm is seeking lead plaintiffs with a September 28, 2026 deadline.

    BERXTCAPR
  4. Na

    CAPR Stock Skyrockets 144% in a Month: What Is Driving the Rally?

    Capricor Therapeutics (CAPR) shares surged 144% over the past month following positive phase III HOPE-3 data showing a 54% reduction in upper-limb function decline for its deramiocel cell therapy in Duchenne muscular dystrophy. After an initial FDA rejection, the company refined its indication to focus on upper-limb function, and the FDA accepted the resubmission with a new PDUFA date of November 22, 2026. The stock rally reflects renewed investor optimism despite substantial regulatory risk.

    CAPRPGENACIUALDX
  6. Na

    Digital Realty Expands Into Turkiye With Strategic Data Center JV

    Digital Realty has announced a strategic joint venture with Ronesans Infrastructure to enter the Turkish market. The partnership will develop a next-generation data center campus in Ankara with over 22MW of carrier-neutral IT capacity, with completion targeted for 2028. Plans also include expansion into Istanbul to create a connected regional infrastructure platform serving cloud, AI, and enterprise digital infrastructure demands.

    DLRDLRPJDLRPKDLRPLLAMR